Online inquiry

IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2320MR)

This product GTTS-WQ2320MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD200 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001004196.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4345
UniProt ID P41217
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2320MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3415MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ9995MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ179MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ10932MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ3366MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ1621MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ10301MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ13046MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW